These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 25770020)

  • 21. Competition policy for health care provision in the Netherlands.
    Schut FT; Varkevisser M
    Health Policy; 2017 Feb; 121(2):126-133. PubMed ID: 27923494
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk adjusted premium subsidies and risk sharing: key elements of the competitive sickness fund market in the Netherlands.
    Lamers LM; van Vliet RC; van de Ven WP
    Health Policy; 2003 Jul; 65(1):49-62. PubMed ID: 12818745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Healthcare reforms and cost reduction strategies in Europe: the cases of Germany, UK, Switzerland, Italy and France.
    Simonet D
    Int J Health Care Qual Assur; 2010; 23(5):470-88. PubMed ID: 20845678
    [TBL] [Abstract][Full Text] [Related]  

  • 24. What can Europe learn from the managed care backlash in the United States?
    Duijmelinck D; van de Ven W
    Health Policy; 2016 May; 120(5):509-18. PubMed ID: 27055353
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Managed care and efficient rationing.
    Rosenthal MB; Newhouse JP
    J Health Care Finance; 2002; 28(4):1-10. PubMed ID: 12148660
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rationing and competition in the Dutch health-care system.
    Schut FT; Van de Ven WP
    Health Econ; 2005 Sep; 14(Suppl 1):S59-74. PubMed ID: 16161190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acceptance of selective contracting: the role of trust in the health insurer.
    Bes RE; Wendel S; Curfs EC; Groenewegen PP; de Jong JD
    BMC Health Serv Res; 2013 Oct; 13():375. PubMed ID: 24083663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advice from the health insurer as a channelling strategy: a natural experiment at a Dutch health insurance company.
    Bes RE; Curfs EC; Groenewegen PP; de Jong JD
    BMC Health Serv Res; 2018 Nov; 18(1):832. PubMed ID: 30400978
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Needs for further improvement: risk adjustment in the German health insurance system.
    Buchner F; Wasem J
    Health Policy; 2003 Jul; 65(1):21-35. PubMed ID: 12818743
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Health insurance in India: need for managed care expertise.
    Thomas TK
    Am J Manag Care; 2011 Feb; 17(2):e26-33. PubMed ID: 21473657
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Barriers of access to care in a managed competition model: lessons from Colombia.
    Vargas I; Vázquez ML; Mogollón-Pérez AS; Unger JP
    BMC Health Serv Res; 2010 Oct; 10():297. PubMed ID: 21034481
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High cost pool or high cost groups-How to handle high(est) cost cases in a risk adjustment mechanism?
    Schillo S; Lux G; Wasem J; Buchner F
    Health Policy; 2016 Feb; 120(2):141-7. PubMed ID: 26806676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk equalization in The Netherlands: an empirical evaluation.
    Van Kleef RC; Van Vliet RC; Van de Ven WP
    Expert Rev Pharmacoecon Outcomes Res; 2013 Dec; 13(6):829-39. PubMed ID: 24175733
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preconditions for efficiency and affordability in competitive healthcare markets: are they fulfilled in Belgium, Germany, Israel, the Netherlands and Switzerland?
    van de Ven WP; Beck K; Buchner F; Schokkaert E; Schut FT; Shmueli A; Wasem J
    Health Policy; 2013 Mar; 109(3):226-45. PubMed ID: 23399042
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Managed competition in The Netherlands: lessons from five years of health care reform.
    van de Ven W; Rutten F
    Aust Health Rev; 1995; 18(1):9-27. PubMed ID: 10141966
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Free choice of sickness funds in regulated competition: evidence from Germany and The Netherlands.
    Gress S; Groenewegen P; Kerssens J; Braun B; Wasem J
    Health Policy; 2002 Jun; 60(3):235-54. PubMed ID: 11965333
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Managed competition: the policy context.
    Scotton R
    Aust Health Rev; 1999; 22(2):103-21. PubMed ID: 10558292
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is there a business case for quality in The Netherlands? A critical analysis of the recent reforms of the health care system.
    Custers T; Arah OA; Klazinga NS
    Health Policy; 2007 Jul; 82(2):226-39. PubMed ID: 17070956
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Building a competitive insurance system: Switzerland's strategy for managed-care healthcare.
    Zweifel P
    Pharmacoeconomics; 2006 Dec; 24 Suppl 2():111-9. PubMed ID: 23389494
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk adjustment and risk sharing: the Israeli experience.
    Shmueli A; Chernichovsky D; Zmora I
    Health Policy; 2003 Jul; 65(1):37-48. PubMed ID: 12818744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.